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Abstract
Understanding the genetic causes of kidney disease is essential for accurate diag-
nosis and could lead to improved therapeutic strategies and prognosis. To accu-
rately and promptly identify the genetic background of kidney diseases, we
applied a targeted next-generation sequencing gene panel including 203 genes
associated with kidney disease, as well as diseases originating in other organs
with mimicking symptoms of kidney disease, to analyze 51 patients with non-
specific nephrogenic symptoms, followed by validation of its efficacy as a diag-
nostic tool. We simultaneously screened for copy number variants (CNVs) in each
patient to obtain a higher diagnostic yield (molecular diagnostic rate: 39.2%).
Notably, one patient suspected of having Bartter syndrome presented with
chloride-secreting diarrhea attributable to homozygous SLC26A3 variants. Addi-
tionally, in eight patients, NGS confirmed the genetic causes of undefined kidney
diseases (8/20, 40%), and initial clinical impression and molecular diagnosis were
matched in 11 patients (11/20, 55%). Moreover, we found seven novel patho-
genic/likely pathogenic variants in PKD1, PKHD1, COL4A3, and SLC12A1 genes,
with a possible pathogenic variant in COL4A3 (c.1229G>A) identified in two
unrelated patients. These results suggest that targeted NGS-panel testing per-
formed with CNV analysis might be advantageous for noninvasive and compre-
hensive diagnosis of suspected genetic kidney diseases.
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1 | INTRODUCTION
Kidney diseases represent a heterogeneous group of disorders,
including monogenic disorders, such as autosomal dominant/reces-
sive polycystic kidney disease (ADPKD/ARPKD), as well as complex
genetic diseases, such as steroid resistance nephrotic syndrome
(SRNS), Alport syndrome, and congenital anomalies of the kidney
and urinary tract (CAKUT).1 Kidney diseases, especially those with a
chronic course, can lead to permanent and irreversible deterioration
of renal function. Therefore, accurate and prompt diagnosis is essen-
tial for improving outcomes for patients with these diseases; how-
ever, this can be difficult due to either nonspecific symptoms and
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signs or clinically silent symptoms in the early stages of disease.
Additionally, this is complicated by several systemic diseases or dis-
eases originating from other organs, that can present symptoms sim-
ilar to those from confined kidney, including various structural
abnormalities, electrolyte imbalances, or metabolic acidosis/alkalo-
sis. For example, renal cysts, which are structural abnormalities in
the kidney, can also be identified in various multisystemic diseases,
such as tuberous sclerosis complex, oral-facial-digital syndrome, and
coloboma syndrome, as well as ADPKD or ARPKD.2,3 Therefore,
diagnosing the precise underlying causes of kidney diseases with
nonspecific symptoms using conventional laboratory and imaging
diagnostic tools can be challenging.
An invasive procedure, such as renal biopsy, could often be per-
formed to identify the underlying etiology of this disease group; how-
ever, it is limited by the range of conditions that it can successfully
confirm and is associated with a risk of complications, including bleed-
ing.4-7 Moreover, this diagnostic method often fails to uncover a cor-
rect diagnosis in very early or late stages of diseases.1,8
According to several reports, 10% of the population with adult
chronic kidney disease (CKD) and almost all pediatric patients who
progress to end-stage renal disease are identified as having inherited
kidney disease.9-12 Therefore, the importance of genetic testing
should not be overlooked during the diagnostic workup of kidney dis-
eases. An accurate genetic diagnosis could provide proper treatment
options for the patient in the early phase, leading to prevention of the
rapid worsening of the disease and playing a pivotal role in selecting
relative kidney donors for transplantation or family planning. How-
ever, identifying disease-causing genes is challenging because of the
complexity of the genetic background.
The efforts to improve the capabilities of genetic testing have
been developed in recent years, and the revolution of next-generation
sequencing (NGS) has enabled cost-effective simultaneous sequenc-
ing of a broad set of candidate genes. Recently, several studies
reported the effectiveness of NGS in identifying various genetic fac-
tors in inherited kidney diseases, including glomerular nephropathy,
steroid-resistant nephrotic syndrome, and cystic kidney disease.2,13-17
However, most studies are limited by only analyzing well-known caus-
ative genes of inherited kidney disease. Additionally, differential diag-
noses of diseases originating in other organs, which could result in
symptoms and signs mimicking kidney disease, have not been identi-
fied. Moreover, almost all of these studies were performed on
patients of mainly European descent; therefore, these results might
not represent all ethnic populations.
Here, we applied a targeted NGS panel and simultaneous analysis
of copy number variation (CNV) to elucidate the genetic causes of
suspected genetic kidney diseases in an Asian population. Addition-
ally, we confirmed the feasibility of this diagnostic method for the dif-
ferential diagnosis of diseases originating from the kidney or another
organ but presenting with overlapping symptoms and signs according
to the NGS panel. To validate the diagnostic efficacy of this NGS
panel, we tested 51 Korean patients with symptoms of kidney disease
and suspected of having inherited kidney disease and referred for
evaluation to determine possible genetic causes.
2 | MATERIALS AND METHODS
2.1 | Patient selection and study design
From January 2018 to August 2019, 51 unrelated, genetically
undiagnosed patients were enrolled for targeted NGS testing using a
comprehensive kidney disease panel developed in the Department of
Clinical Genetics at Severance Children's Hospital (Seoul, Korea). All
patients had one or more of the following symptoms/signs: protein-
uria, hematuria, electrolyte imbalance, metabolic alkalosis/acidosis, or
abnormal kidney structure. We retrospectively reviewed the pedigree
information, previous medical history, physical examination findings,
and any additional investigative results (e.g., ophthalmologic and otol-
ogy examinations) in the electronic medical records of each patient.
Additionally, we collected the available results based on segregation
analyses of family members of each patient. This information was col-
lected under anonymity in a routine diagnostic process, and the study
protocol was approved by the Institutional Review Board of the
Yonsei University Health System (IRB 4-2019-0227). Informed con-
sent for the genetic testing was obtained from each patient or their
legal guardians if the patient was aged <19 years.
2.2 | Panel design
First, we searched for symptoms and signs resembling those observed
in genetic kidney diseases using PubMed, Embase, and MEDLINE.
Accordingly, we searched for the following symptoms and signs: pro-
teinuria, hematuria, electrolyte imbalance, metabolic alkalosis/acido-
sis, and abnormal kidney structure. Based on data from the Human
Genome Mutation Database (HGMD), Online Mendelian Inheritance
in Man (OMIM) database (http://www.ncbi.nlm.nih.gov/omim), and an
extensive literature review using PubMed, we extracted and opti-
mized 203 disease-causing genes (Table 1). The last search was per-
formed on October 10, 2020.
2.3 | DNA preparation
We collected 3 ml of peripheral blood in EDTA tubes from each
patient and extracted the genomic DNA from leukocytes using a
DNeasy blood and tissue kit (Qiagen, Hilden, Germany) according to
manufacturer instructions. The quality of isolated DNA was checked
using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Wal-
tham, MA, USA).
2.4 | Library preparation, target capture, and DNA
sequencing
We constructed a DNA sequencing library using the TruSeq DNA
Library Prep Kits protocol according to manufacturer instructions
(TruSeq DNA Library Prep Kits,, FC-121-2003; Illumina, Carlsbad, CA,
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TABLE 1 Genes (n = 203) included in the panel of kidney diseases
Gene Cytogenic location Inheritance Gene accession number Disease association
ACTN4 19q13.2 AD NM_004924 Glomerulosclerosis, focal segmental, 1
ADAMTS13 9q34.2 AR NM_139025 Thrombotic thrombocytopenic purpura, familial
AGTR1 3q24 AR NM_000685 Renal tubular dysgenesis
AGXT 2q37.3 AR NM_000030 Hyperoxaluria, primary, type 1
AHI1 6q23.3 AR NM_017651 Joubert syndrome 3
ALG8 11q14.1 AR NM_019109 Polycystic liver disease 3 with or without kidney cysts
ALMS1 2p13.1 AR NM_015120 Alström syndrome, retinitis pigmentosa, sensorineural hearing
loss
ANKS6 9q22.33 AR NM_173551 Nephronophthisis 16
AP2S1 19q13.32 AD NM_001301076 Hypocalciuric hypercalcemia, type III
APRT 16q24.3 AR NM_000485 Adenine phosphoribosyltransferase deficiency
AQP2 12q13.12 AD/AR NM_000486 Diabetes insipidus, nephrogenic
ARHGDIA 17q25.3 AR NM_001185077 Nephrotic syndrome, type 8
ARL13B 3q11.1-q11.2 AR NM_182896 Joubert syndrome 8
ARNT2 15q25.1 AR NM_014862 Webb-Dattani syndrome
ATP6V0A4 7q34 AR NM_020632 Renal tubular acidosis, distal, autosomal recessive
ATP6V1B1 2p13.3 AR NM_001692 Renal tubular acidosis with deafness
AVP 20p13 AD NM_000490 Diabetes insipidus, neurohypophyseal
AVPR2 Xq28 XLR NM_000054 Diabetes insipidus, nephrogenic; Nephrogenic syndrome of
inappropriate antidiuresis
B9D2 19q13.2 AR NM_030578 Joubert syndrome 34
BBS10 12q21.2 AR NM_024685 Bardet-Biedl syndrome 10
BBS12 4q27 AR NM_152618 Bardet-Biedl syndrome 12
BBS1 11q13.2 AR/DR Bardet-Biedl syndrome 1
BBS2 16q13 AR NM_031885 Bardet-Biedl syndrome 2
BBS4 15q24.1 AR NM_033028 Bardet-Biedl syndrome 4
BBS9 7p14.3 AR NM_001033604 Bardet-Biedl syndrome 9
BCS1L 2q35 AR NM_004328 Mitochondrial complex III deficiency, nuclear type 1
BICC1 10q21.1 AD NM_025044 Renal dysplasia, cystic, susceptibility to
BSND 1p32.3 AR NM_057176 Bartter syndrome, type 4a; Sensorineural deafness with mild
renal dysfunction
CA2 8q21.2 AR NM_000067 Osteopetrosis, autosomal recessive 3, with renal tubular
acidosis
CA12 15q22.2 AR NM_001218 Hyperchlorhidrosis, isolated
CASR 3q13.3-q21.1 AD NM_000388 Hypocalcemia, autosomal dominant, with Bartter syndrome
CC2D2A 4p15.32 AR NM_001080522 Joubert syndrome 9
CD151 11p15.5 AR NM_004357 Nephropathy with pretibial epidermolysis bullosa and
deafness
CD2AP 6p12.3 AD/AR NM_012120 Glomerulosclerosis, focal segmental, 3
CEP164 11q23.3 AR NM_014956 Nephronophthisis 15
CEP290 12q21.32 AR NM_025114 Bardet-Biedl syndrome 14; Joubert syndrome 5
CEP41 7q32.2 AR NM_018718 Joubert syndrome 15
CFH 1q31.3 AD/AR NM_000186 Hemolytic uremic syndrome, atypical, susceptibility to, 1
CFHR5 1q31.3 AD NM_030787 Nephropathy due to CFHR 5 days eficiency
CLCN5 Xp11.23 XLR NM_000084 Dent disease; Nephrolithiasis, type I; Proteinuria, low
molecular weight, with hypercalciuric nephrocalcinosis
CLCNKB 1p36.13 AR/DR NM_000085 Bartter syndrome, type 3
Bartter syndrome, type 4b, digenic
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TABLE 1 (Continued)
Gene Cytogenic location Inheritance Gene accession number Disease association
CLDN10 13q32.1 AR HELIX syndrome
CLDN16 3q28 AR NM_006580 Hypomagnesemia 3, renal
CLDN19 1p34.2 AR NM_148960 Hypomagnesemia 5, renal, with ocular involvement
CNNM2 10q24.32 AD NM_017649 Hypomagnesemia 6, renal
COL4A1 13q34 AD NM_001303110 Angiopathy, hereditary, with nephropathy, aneurysms, and
muscle cramps
COL4A3 2q36.3 AD/AR NM_012120 Alport syndrome
COL4A4 2q36.3 AR NM_000091 Alport syndrome, familiar hematuria
COL4A5 Xq22.3 X-linked NM_000092 Alport syndrome
COQ2 4q21.22-q21.23 AR NM_015697 Mitochondrial disease, encephalopathy/isolated nephropathy
COQ6 14q24.3 AR NM_182476 Nephrotic syndrome ± sensorineural deafness
CTNS 17p13.2 AR NM_004937 Cystinosis, nephropathic
CUBN 10p13 AR NM_001081 Imerslund-Grasbeck syndrome
CYP11B2 3q24.3 AR NM-000498 Hypoaldosteronism, congenital, due to CMO I deficiency
DGKE 17q22 AR NM_003647 Nephrotic syndrome, type 7
DGUOK 2p13.1 AR NM_080916 Mitochondrial DNA depletion syndrome 3
DMP1 4q22.1 AR NM_001079911 Hypophosphatemic rickets
DHCR7 11q13.4 AR NM_001360 Smith-Lemli-Opitz syndrome
EGF 10p13 AR NM_001178130 Hypomagnesemia 4, renal
EGFR 7p11.2 AR Inflammatory skin and bowel disease, neonatal, 2
EHHADH 3q27.2 AD NM_001166415 Fanconi renotubular syndrome 3
EYA1 8q13.3 AD NM_000503 Branchiootorenal syndrome 1, with or without cataracts
FAM58A Xq28 XLD NM_152274 STAR syndrome
FAN1 15q13.3 AR NM_014967 Interstitial nephritis, karyomegalic
FGF23 12p13.32 AD NM_020638 Hypophosphatemic rickets
FN1 2q35 AD NM_212476 Glomerulopathy with fibronectin deposits 2
FRAS1 4q21.21 AR NM_001166133 Fraser syndrome 1
FREM1 9p22.3 AD/AR NM_144966 Bifid nose with or without anorectal and renal anomalies
FREM2 13q13.3 AR NM_207361 Fraser syndrome 2
FXYD2 11q23.3 AD NM_021603 Hypomagnesemia 2, renal
GATA3 10p14 AD NM_001002295 Hypoparathyroidism, sensorineural deafness, and renal
dysplasia
GLA Xq22.1 XLR NM_000169 Fabry disease
GLB1 3p22.3 AR NM_000404 Mucopolysaccharidosis type IVB (Morquio)
GLIS2 16p13.3 AR NM_032575 Nephronophthisis 7
GLIS3 9p24.2 AR NM_152629 Diabetes mellitus, neonatal
GNA11 19p13.3 AD NM_002067 Hypocalciuric hypercalcemia, type II
HNF1B 17q12 AD NM_000458 Renal cysts and diabetes syndrome
HPRT1 Xq26.2-q26.3 XLR NM_000194 HPRT-related gout, Lesch–Nyhan syndrome
HSD11B2 16q22.1 AR NM_000196 Apparent mineralocorticoid excess
IFT122 3q21.3-q22.1 AR NM_018262 Cranioectodermal dysplasia 1
IFT140 16p13.3 AR NM_014714 Short-rib thoracic dysplasia 9 with or without polydactyly
IFT172 2p23.3 AR NM_015662 Short-rib thoracic dysplasia 10 with or without polydactyly
INF2 14q32.33 AD NM_022489 Glomerulosclerosis, focal segmental, 5
INPP5E 9q34.3 AR NM_019892 Joubert syndrome 1
INVS 9q31.1 AR NM_014425 Nephronophthisis 2, infantile
IQCB1 3q13.33 AR NM_014642 Senior-Loken syndrome 5
(Continues)
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TABLE 1 (Continued)
Gene Cytogenic location Inheritance Gene accession number Disease association
ITGB4 17q25.1 AR NM_000213 Epidermolysis bullosa, junctional, with pyloric atresia
KAL1 Xp22.31 XLR NM_000216 Hypogonadotropic hypogonadism 1 with or without anosmia
(Kallmann syndrome 1)
KANK2 19p13.2 AR NM_015493 Nephrotic syndrome, type 16
KCNJ1 11q24.3 AR NM_000220 Bartter syndrome, type 2
KCNJ10 1q23.2 AR NM_002241 SESAME syndrome
KIF7 15q26.1 AR NM_198525 Joubert syndrome 12
LAMB2 3p21.31 AR NM_002292 Pierson syndrome
LCAT 16q22.1 AR NM_000229 Norum disease
LMX1B 9q33.3 AD NM_002316 Nail patella syndrome; FSGS without extrarenal involvement
LRP2 2q31.1 AR NM_004525 Donnai-Barrow syndrome
LYZ 12q15 AD NM_000239 Amyloidosis, renal
MAFB 20q12 AD NM_005461 Multicentric carpotarsal osteolysis syndrome
MED28 4p15.32 AR NM_025205 nephrotic syndrome
MKKS 20p12.2 AR NM_018848 Bardet-Biedl syndrome 6
MKS1 17q22 AR NM_017777 Bardet-Biedl syndrome 13, Joubert syndrome 28
MYH9 22q12.3 AD, association NM_002473 MYH9-related disease; Epstein and Fechtner syndromes
MMACHC 1p34.1 AR NM_015506 Methylmalonic aciduria and homocystinuria, cblC type
MYO1E 15q22.2 AR NM_004995 Glomerulosclerosis, focal segmental, 6
NEK1 4q33 AD/AR NM_001199397 Short-rib thoracic dysplasia 6 with or without polydactyly
NEK8 17q11.2 AR NM_178170 Renal-hepatic-pancreatic dysplasia 2
NNT 5p12 AR NM_012343 Glucocorticoid deficiency 4, with or without mineralocorticoid
deficiency
NOTCH2 1p12 AD NM_024408 Hajdu-Cheney syndrome
NPHP1 2q13 AR NM_000272 Joubert syndrome 4, Nephronophthisis 1, juvenile
NPHP3 3q22.1 AR NM_153240 Nephronophthisis 3
NPHP4 1p36.31 AR NM_001291593 Nephronophthisis 4
NPHS1 19q13.12 AR NM_004646 Nephrotic syndrome, type 1
NPHS2 1q25.2 AR NM_014625 Nephrotic syndrome, type 2
NR0B1 Xp21.2 XLR NM_000475 Adrenal hypoplasia, congenital
NR3C2 4q31.23 AD NM_000901 Pseudohypoaldosteronism type I, autosomal dominant
NUP214 9q34.13 AR NM_001318324 Encephalopathy, acute, infection-induced, susceptibility to, 9
OCRL Xq26.1 XLR NM_000276 Dent disease 2, Lowe syndrome
OFD1 Xp22.2 XLR NM_003611 Joubert syndrome 10
PAX2 10q24.31 AD NM_000278 Glomerulosclerosis, focal segmental, 7
PCCA 13q32.3 AR NM_000282 Propionicacidemia
PDSS2 6q21 AR NM_020381 Leigh syndrome
PHEX Xp22.11 XLD NM_000444 Hypophosphatemic rickets, X-linked dominant
PKD1 16p13.3 AD NM_000296 Polycystic kidney disease 1
PKD2 4q22.1 AD NM_000297 Polycystic kidney disease 2
PKHD1 6p12.3-p12.2 AR NM_138694 Polycystic kidney disease 4, with or without hepatic disease
PLCE1 10q23.33 AR NM_016341 Nephrotic syndrome, type 3
PLVAP 19p13.11 AR NM_031310 Diarrhea 10, protein-losing enteropathy type
POMC 2p23.3 AR NM_001035256 Obesity, adrenal insufficiency, and red hair due to POMC
deficiency
PTPRO 12p12.3 AR NM_030667 Nephrotic syndrome, type 6
REN 1q32.1 AR NM_000537 Renal tubular dysgenesis
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Gene Cytogenic location Inheritance Gene accession number Disease association
RPGRIP1L 16q12.2 AR NM_015272 Joubert syndrome 7
RRM2B 8q22.3 AR NM_001172477 Mitochondrial DNA depletion syndrome 8A
(encephalomyopathic type with renal tubulopathy)
SALL1 16q12.1 AD NM_002968 Townes-Brocks branchiootorenal-like syndrome
SALL4 20q13.3 AD NM_001318031 IVIC syndrome
SARS2 19q13.2 AR NM_017827 Hyperuricemia, pulmonary hypertension, renal failure, and
alkalosis
SCARB2 4q21.1 AR NM_005506 Action myoclonus-renal failure syndrome ± hearing loss
SCNN1A 12p13.31 AD NM_001038 Liddle syndrome 3, Bronchiectasis with or without elevated
sweat chloride 2
SCNN1B 16p12.2 AD NM_000336 Liddle syndrome 1, Bronchiectasis with or without elevated
sweat chloride 1
SCNN1G 16p12.2 AD NM_001039 Liddle syndrome, Bronchiectasis with or without elevated
sweat chloride 3
SDCCAG8 1q43-44 AR NM_006642 Bardet-Biedl syndrome 16
SIX5 19q13.32 NM_175875 Branchiootorenal syndrome 2
SLC12A1 15q21.1 AR NM_000338 Bartter syndrome, type 1
SLC12A3 16q13 AR NM_000339 Gitelman syndrome
SLC22A12 11q13.1 AR NM_144585 Hypouricemia, renal
SLC26A3 7q22.3-q31.1 AR NM_000111 Diarrhea 1, secretory chloride, congenital
SLC2A2 3q26.2 AR NM_000340 Fanconi-Bickel syndrome
SLC34A1 5q35.3 AR NM_003052 Fanconi renotubular syndrome 2
SLC34A3 9q34.3 AR NM_080877 Hypophosphatemic rickets with hypercalciuria
SLC3A1 2p21 AD/AR NM_000341 Cystinuria
SLC4A1 17q21.31 AD/AR NM_000342 Renal tubular acidosis, distal
SLC4A4 4q13.3 AR NM_003759 Renal tubular acidosis, proximal, with ocular abnormalities
SLC5A2 16p11.2 AD/AR NM_003041 Renal glucosuria
SLC6A19 5p15.33 AD NM_001003841 Hyperglycinuria
SLC6A20 3p21.31 AD NM_020208 Hyperglycinuria
SLC7A7 14q11.2 AR NM_001126105 Lysinuric protein intolerance
SLC7A9 19q13.11 AD/AR NM_001126335 Cystinuria
SLC9A3 5p15.33 AR Diarrhea 8, secretory sodium, congenital
SLC9A3R1 17q25.1 AD NM_004252 Nephrolithiasis/osteoporosis, hypophosphatemic, 2
SMARCAL1 2q35 AR NM_014140 Schimke immuno-osseous dysplasia
SOX17 8q11.23 AD NM_022454 Vesicoureteral reflux 3
SPINK5 5q32 AR NM_001127698 Netherton syndrome
SPINT2 19q13.2 AR NM_001166103 Diarrhea 3, secretory sodium, congenital, syndromic
STAR 8p11.23 AR NM_000349 Lipoid adrenal hyperplasia
TCTN1 12q24.11 AR NM_024549 Joubert syndrome 13
TMEM216 11q12.2 AR NM_016499 Joubert syndrome 2
TMEM237 2q33.1 AR NM_152388 Joubert syndrome 14
TMEM67 8q22.1 AR NM_153704 Joubert syndrome 6, Nephronophthisis 11
TRIM32 9q33.1 AR NM_012210 Bardet-Biedl syndrome 11
TRPC6 11q22.1 AD NM_004621 Glomerulosclerosis, focal segmental, 2
TTC21B 2q24.3 AD/AR NM_024753 Nephronophthisis 12
TTC8 14q31.3 AR NM_144596 Bardet-Biedl syndrome 8
UMOD 16p12.3 AD NM_001008389 Uromodulin-associated kidney disease
UPK3A 22q13.31 UD NM_006953 Involvement renal dysplasia, possible
(Continues)
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USA). Briefly, DNA in each sample was sheared to 250bp sequences,
tagged, and then purified according to fragment size with magnetic
beads (AMPure XP, Beckman Coulter, IN, USA). We subsequently per-
formed repair, phosphorylation, and adenylation of the 30 ends and
isolated the precaptured amplified 300- to 500-bp fragments. We
then performed targeted sequence, up to 15 bp from the exon of the
target genes based on hg19, capture according to TruSeq Custom
Enrichment Kit protocol (FC-123-1096, Illumina). DNA sequencing
was performed on a V2 flow cell using MiSeq sequencer (Illumina),
generating 150 bp paired-end reads. Image analysis and base calling
were performed using the Illumina pipeline. The yield of each DNA
sample averaged 2 GB of raw data with a 150-fold mean sequencing
depth of the targeted regions.18,19 Sequenced reads were mapped to
the human reference genome (GRCh37), and sequencing alignment
was performed using the Burrows-Wheeler Aligner software
package.20
2.5 | CNV analysis
For CNV detection, we applied ExomeDepth with default parame-
ters.21 ExomeDepth uses a robust model of the read count data to call
CNVs by comparing the test exome data to a matched optimized-
aggregate reference set, which is built with combined exomes from
the same batch to maximize the power to handle technical variability
between samples. This method was applied to the targeted NGS
sequencing data sets to detect pathogenic CNVs, and the identified
CNVs were confirmed through multiplex ligation-dependent probe
amplification or real-time quantitative PCR (RT-qPCR).
2.6 | Sanger sequencing and RT-qPCR
We performed Sanger sequencing for validation and segregation anal-
ysis of variants detected by NGS testing. RT-qPCR was performed for
segregation analysis of CNVs using primers designed according to the
oligonucleotide sequences of the variants.
2.7 | Interpretation and analysis of the detected
variants
We examined the NGS data and prioritized DNA variants according to
clinical relevance using the following parameters: (1) sequence quality;
(2) allele frequency (according to the Exome Aggregation Consortium
[ExAC], dbSNP database, and Korean Reference Genome Database
[KRGDB; http://coda.nih.go.kr/]); and (3) presence in HGMD, OMIM,
dbSNP, or ClinVar. Real or possible damage of variants was predicted
using in silico prediction algorithms, including Polymorphism
Phenotyping version 2 (PolyPhen-2) and Sorting Tolerant from Intol-
erant (SIFT; https://sift.bii.a-star.edu.sg/). After compressive analysis
of all results, we classified the identified variants into a five-tier sys-
tem as pathogenic (P), likely pathogenic (LP), variant of unknown sig-
nificance (VUS), likely benign, or benign according to the American
College of Medical Genetics and Genomics (ACMG) guidelines.22
According to the inheritance pattern of the disease, we considered
results positive if one or two P/LP variants in one disease-related
gene was identified according to the inheritance patterns of diseases.
If only a VUS or one P/LP variant was detected in a gene with an
autosomal recessive (AR) inheritance pattern, we considered the result
nondiagnostic. We reported cases without any VUS or P/LP as nega-
tive results.
3 | RESULTS
3.1 | Patient characteristics
A total of 51 unrelated patients were included in this study (median
age: 11.6 years [range: 0–46 years]). Among these, 36 (70.6%) were
TABLE 1 (Continued)
Gene Cytogenic location Inheritance Gene accession number Disease association
VIPAS39 14q24.3 AR NM_022067 Arthrogryposis, renal dysfunction, and cholestasis 2
VPS33B 15q26.1 AR NM_018668 Arthrogryposis, renal dysfunction, and cholestasis 1
WDR19 4p14 AR NM_001317924 Nephronophthisis 13, Senior-Loken syndrome 8
WDR35 2p24.1 AR NM_020779 Short-rib thoracic dysplasia 7 with or without polydactyly
WNK1 12p13.33 AD NM_018979 Pseudohypoaldosteronism, type IIC
WNK4 17q21.2 AD NM_001321299 Pseudohypoaldosteronism, type IIB
WNT4 1p36.12 AD NM_030761 Mullerian aplasia and hyperandrogenism
WT1 11p13 AD NM_000378 Nephrotic syndrome, type 4; Denys–Drash and Frasier
syndrome
XPNPEP3 22q13.2 AR NM_022098 Nephronophthisis-like nephropathy 1
ZMPSTE24 1p34.2 AR NM_005857 Mandibuloacral dysplasia with type B lipodystrophy
ZNF423 16q12.1 AD/AR 604 557 Joubert syndrome 19; Nephronophthisis 14
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; UD, undetermined.
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male, and 15 (29.4%) were female. Five patients (9.8%) had a family
history related to kidney disease, and three (5.9%) had undergone
renal biopsy due to hematuria before the NGS panel test. The reasons
for referral were as follows: structural abnormalities in kidneys
detected by computed tomography or sonogram in 16 patients, urinal-
ysis abnormalities in 21 patients, electrolyte imbalances in 12 patients,
and renal failure in two patients (Table 2).
3.2 | Diagnostic yield of NGS
In total, the final diagnostic yield was 39.2% (20/51), which included
the diagnostic group when P/LP variants or CNV abnormalities in our
NGS panel test matched the symptoms of patients. The final molecu-
lar diagnosis confirmed by our targeted NGS panel classified patients
into the following diseases: four patients with ADPKD, one patient
with ARPKD, three patients with Alport syndrome, one patient with
hyperoxaluria type 1, three patients with Bartter syndrome, two
patients with Gitelman syndrome, one patient with
SLC4A1-associated renal tubular acidosis, and one patient with con-
genital chloride secretory diarrhea. Moreover, we identified four
patients exhibiting dysmorphic features and global delayed develop-
ment in addition to several renal cysts in both kidneys with CNV
abnormalities on chromosome (1p36 [2 patients] and 17q12
[2 patients]). Nondiagnostic results were showed for 31 patients with
VUSs only, as well as for four patients with only one P/LP variant in
the disease gene with an AR-inheritance trait.
The first clinical symptoms of the diagnosed patients were as
follows: urinalysis abnormality, including hematuria or proteinuria
(4/21; 19.0%), structural abnormalities in the kidney (9/16; 56.3%),
and electrolyte imbalances (7/12; 58.3%). The details of the
patients confirmed by molecular diagnosis are summarized in
Table 3.
Among five patients with related familial medical histories, three
harbored pathogenic variants associated with their symptoms. Their
final diagnosis was ADPKD (one patient), Alport syndrome (one
patient), and SLC4A1-associated distal renal tubular acidosis (one
patient). Among the three patients who had undergone renal biopsy
due to hematuria before the NGS panel test, one was determined to
have one novel LP variant in COL4A3, and two were found to have
the same VUS in COL4A3, which was known to be associated with
Alport syndrome. These results were consistent with their histological
diagnosis.
3.3 | Detection of genetic variants and CNVs
Targeted NGS analysis identified 169 variants in 84 genes, with every
patient having at least one variant. On average, we detected 2.0 vari-
ants, with a maximum of 12 per patient. We detected 27 P/LP vari-
ants of 10 genes in 24 patients. Of these variants, 18 (66.7%) had
been formerly reported as P/LP, whereas 9 (33.3%) had not yet been
reported at the time of our investigation. The mutational types of
these 27 P/LP variants were as follows: 11 missense variants, six non-
sense variants, three frameshift, three small insertion/deletions, two
exonal deletions, and two splicing errors. The most frequently
detected P/LP variants were observed in PKD1 (n = 4; 14.8%),
CLCNKB (n = 4; 14.8%), and SLC12A3 (n = 4; 14.8%).
Additionally, all patients harbored one or more VUS, with
142 VUSs detected in 70 genes. Among these VUSs, the most fre-
quently involved genes were PKD1 (n = 15; 10.6%), PKHD1 (n = 6;
4.2%), and ALMS1 (n = 6; 4.2%). Additionally, we detected five hetero-
zygous CNVs in five patients, although only two of the CNVs (the
1p36 and 17q12 microdeletions) found in four patients were revealed
as pathogenic according to the phenotype of the patients, segregation
analysis, and our literature review.
3.4 | Novel variants
Among the 20 patients with confirmed disease according to our
molecular diagnosis, seven novel variants in seven patients absent
from population databases and our in-house database were identified.
Moreover, two novel exonal deletions were identified in CLCNKB for
two patients (Patient 14 [exon 4 deletions] and Patient 15 [exon 1–14
deletion]).
Among patients with ADPKD with multiple renal cysts, two novel
LP variants of PKD1 were identified, with both were shown to be non-
sense variants (Patient 6 [p.Tyr325Ter] and Patient 8 [p.Cys4020Ter]).
Further, a 5 day old patient with ARPKD and presenting with polycys-
tic dysplastic kidney disease and hypoplastic lung was found to carry
two novel P/LP novel variants in PKHD1. One was a paternally
inherited missense LP variant (p.Val1627Phe), whereas the other was
a maternally inherited frameshift P variant (p.lle3738SerfsTer19).
In the two patients with Alport syndrome, we detected two dif-
ferent novel P/LP variants of COL4A3. Patient 10, a 7-year-old girl,
TABLE 2 The clinical causes for using NGS in the renal disease
panel test
Reasons for NGS Patient number (n)
Structural abnormalities in kidney 16
Polycystic kidney disease 13










Abbreviation: NGS, next-generation sequencing.
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showed recurrent hematuria, and her genetic investigation revealed
a paternally inherited P variant (p.Thr140HisfsTer13) in COL4A3.
Her father also had a history of nephritis and was diagnosed with
Alport syndrome after genetic testing. Additionally, Patient 11 pres-
ented with recurrent hematuria and sensory hearing loss and was
revealed to have a novel LP variant in COL4A3 that could cause a
splicing error (1029 + 1G>A).
Further, we detected a novel P variant (c.888delG) of SLC12A1
in a 15-year-old boy with recurrent hypokalemia and symptoms of
hearing impairment and tremor. His genetic testing showed a pater-
nally inherited novel variant (c.888delG) combined with a maternally
inherited missense P variant (p.Ala400Thr) previously reported in
SLC12A1. Accordingly, he was diagnosed with Bartter syndrome
based on these results.
3.5 | Noteworthy VUSs
Notably, we identified a meaningful VUS in the COL4A3 gene of
two unrelated patients (patients 21 and 22). This missense variant
was clinically classified as a VUS in a well-defined disease gene of
Alport syndrome (c.1229G>A, p.Gly410Glu) according to ACMG
guidelines. Patients 21 and 22 were presenting with proteinuria and
hematuria since her 20s and the age of 5. Their renal pathologic
findings revealed an irregular thickening of the GBM. Based on the
clinical symptoms and biopsy findings, they were clinically suspected
of having Alport syndrome. Their NGS panel testing identified the
same heterozygous VUS (c.1229G>A, p.Gly410Glu) in COL4A3, with
Sanger sequencing confirming the detected variant. The variant was
absent from public genome databases (ExAC, 1000 Genomes data,
and our in-house database), and the structure and function of the
protein were predicted as likely damaged according to Polyphen2
(PPH2 score: 1.0). The altered residue was revealed to be highly
conserved across vertebrate species. Given that this variant was
consistently identified in two unrelated patients with highly
suspected Alport syndrome from their clinical symptoms and patho-
logical results, along with the results of variant analysis, this
suggested a high probability of being reclassified as an LP/P variant.
Although further analyses of the genetic consequences based on
the family members were recommended to assess the exact patho-
genic indication of this VUS, these tests could not be conducted due
to lack of agreements by the family members of the patients
(Table 4).
3.6 | Correlation between clinically suspected
diseases and molecular diagnosis
Of the 20 patients for whom disease was confirmed through molec-
ular diagnosis based on our genetic test, clinically suspected diagno-
sis and genetic diagnosis were matched in 11 patients (11/20, 55%),
including three patients with ADPKD, one patient with ARPKD, two
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syndrome, and two patients with Gitelman syndrome. By contrast, the
results of our NGS panel reclassified the final diagnosis from initial
clinical diagnosis in one patient (5%). This 11-month-old boy was ini-
tially clinically diagnosed with Bartter syndrome before genetic testing
and finally diagnosed with chloride-secretion diarrhea originating from
the intestine and not from the kidneys (Patient 20).
In eight patients, the NGS panel test played an essential role in
confirming the genetic cause of their previously undefined kidney dis-
ease (8/20, 40%), including one patient with ADPKD with cystic kid-
ney (Patient 5), one patient with Alport syndrome (Patient 12), one
patient with hyperoxaluria type 1 (Patient 13), one patient with
SLC4A1-associated renal tubular acidosis (Patient 19) and four
patients with CNVs abnormalities (Patients 1, 2, 3 and 4). Detailed
results are shown in Figure 1.
4 | DISCUSSION
In this study, we analyzed the genetic diagnosis of 51 unrelated
patients with clinically suspected, inherited kidney disease using a
customized NGS panel that included genes related to broad symptoms
of kidney disease. Consequently, a total of 39.2% (20/51) of patients
were confirmed as having a genetic disease.
Several studies analyzed results using targeted NGS panels to
diagnose inherited kidney diseases. Sen et al. reported the results of
analysis of an SRNS-targeted diagnostic gene panel performed for
302 patients, confirming genetic diagnoses in 26.6% of the patients.23
Another study of 44 patients with typical PKD who underwent
targeted NGS testing with 63 related genes revealed 48 related muta-
tion sites in PKD1 and PKD2.24
It should be noted that in the present study, the NGS panel used
did not focus on genes limited to kidney diseases but rather included
a broad set of 203 genes related to diseases that might mimic the
symptoms of inherited kidney diseases, even though diseases origi-
nate from other organs. This approach could facilitate the accurate
diagnosis of inherited kidney diseases, as well as the prompt differen-
tiation of genetic diseases with overlapping symptoms, whether these
might have originated in the confined kidney or other organs.
One of the advantageous characteristics of this NGS panel was
evident based on the notable case of patient 20. This patient visited
our hospital for the first time exhibiting lethargy. He had been born at
35.4 weeks of gestation from healthy parents and had two healthy
older brothers, with no other notable family history. Fifteen days after
birth, he developed abdominal distension suggestive of neonatal nec-
rotizing enterocolitis and received ileostomy surgery. After 2 months,
he received another surgery for segmental resection of a 7.9-cm
ischemic ileum lesion and to repair the ileostomy site. On admission,
he showed severe hyponatremia and hypokalemic hypochloremic
metabolic alkalosis (serum sodium: 128 mmol/L; potassium:
2.5 mmol/L; and chloride: 67 mmol/L; pH 7.652; pCO2: 32.5 mmHg;
pO2: 103.0 mmHg; and HCO3: 36.3 mmol/L). Abdominal sonography
showed diffuse renal disease with bilateral renal enlargement. Given
F IGURE 1 Correlations between clinical suspicion and results of molecular analysis. ADPKD, autosomal dominant polycystic kidney disease;
AS, Alport syndrome; BS, Bartter syndrome; GS, Gitelman syndrome; HUS, hemolytic uremic syndrome; TBMD, thin basement membrane
disease; SRNS, steroid resistance nephrotic syndrome [Colour figure can be viewed at wileyonlinelibrary.com]
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these results, Bartter syndrome was initially suspected as a diagnosis,
and he was referred to our study to precisely identify the genetic eti-
ology of his condition. According to the genetic test, we discovered
two homozygous splice-site pathogenic mutations in SLC26A3
(c.2063-1G>T), which encodes a transmembrane glycoprotein that
exchanges chloride and bicarbonate ions across the cell membrane.
His parents were identified as the asymptomatic carriers of
c.2063-1G>T. To confirm the molecular diagnosis, we analyzed the
stool of the patient, finding a sodium level of 120 mmol/L. Although
there were symptoms that could be mistaken as a disease originating
from the kidney, he was finally diagnosed with chloride-secreting diar-
rhea, which differed from the first clinical impression. This result of
the molecular diagnosis offered the chance of appropriate treatment,
focusing salt substitution therapy according to the treatment protocol
of chloride-secreting diarrhea and he has maintained good condition.
Additionally, our findings emphasized the usefulness of CNV anal-
ysis. Recent studies report that most CNVs are likely benign, but that
some specific variants might be related to genetic diseases, such as
neurodevelopmental diseases and various cancers.25-28 NGS based
CNV detection has a reported sensitivity of up to 92% and specificity
of up to 100% for detecting duplications as small as 300 bp and dele-
tions as small as 180 bp in specific genes.29,30 In some inherited kid-
ney diseases, CNVs could also affect susceptibility, and previous
studies have highlighted the need for analyzing CNVs in inherited kid-
ney diseases, such as CAKUT.29,31,32 In the present study, we
detected two known pathogenic CNVs in four patients (Patients 1–4),
with both identified as known CNVs that could lead to kidney- related
symptoms in addition to systemic manifestations. Details of abnormal-
ities in CNVs and patients are described in Table 3.
Regarding the gene variants detected in this study, we found
seven novel P/LP variants and two novel exonal deletions among our
patient group. Further, there was a noticeable VUS identified in
COL4A3, which was found in two unrelated patients. Evidence
suggested that this VUS should be reclassified as P/LP, even though it
is yet assumed to be a VUS according to ACMG guidelines. Further
functional research and segregation analysis of the family of these
patients would help define the pathogenicity of this variant.
The present study had a major advantage (ie, using a targeted
NGS panel focusing on the phenotype of kidney diseases) that
allowed diagnosis of inherited kidney diseases along with differential
diagnoses of diseases based on their origin (kidney or other organs),
despite their presenting symptoms similar to those of kidney disease.
Moreover, we were able to simultaneously obtain relatively high diag-
nostic performance for CNV analysis with the NGS panel. However, a
limitation of the present study is its single-center research design and
inclusion of a small number of patients. Further studies with a larger
number of patients might aid verification of these results in the
future.
Diagnostic approaches using NGS technology could enable accu-
rate and early detection of genetic diseases and minimize the need for
invasive diagnostic procedures, as well as optimize outcomes by
broadening therapeutic options. Moreover, presymptomatic testing
based on family history could be used to detect the genetic causes of
diseases prior to the appearance of overt symptoms, which might
allow application of genetic results for prenatal genetic testing and
counseling in order to prevent the disease.
This study confirmed the efficacy of NGS with CNV analysis as a
diagnostic tool for patients with suspected inherited kidney disease
based on their symptoms. The rapid development of NGS technology
would enable further clinical applicability of this approach for the
diagnosis of inherited kidney disease.
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